What Mepsgen does

MEPSGEN (MEPSGEN Co., Ltd.) is a privately held Korean biotechnology company founded in 2019 and headquartered in Seoul, South Korea. The company develops and commercializes microphysiological systems (MPS) and microfluidic nanoparticle synthesis platforms that enable pharmaceutical companies, biotechnology firms, and academic research institutions to conduct preclinical drug screening, disease modeling, and scalable nanomedicine manufacturing. Its core product lines are ProMEPS® (an automated robotic 3D MPS modeling system for high-throughput drug candidate evaluation), the MEPS-X series of microphysiological chips (covering blood-brain barrier, skin, corneal epithelial, placental, intestinal mucosal, vascular endothelial, blood-retina, and kidney tubular epithelial barrier models, plus organoid and tumor-microenvironment chips), the NanoCalibur® automated nanoparticle synthesis system (available in Mini, Lab, Pro, and GMP variants), and the MST-X microvortex system for scalable lipid nanoparticle production. The company also operates the MG-X nanomedicine pipeline, including MG-PE3 and MG-Sh19 for Alzheimer's disease and MG-GHC24 for glioblastoma.

MEPSGEN generates revenue through three channels: hardware sales of MPS and nanoparticle synthesis instruments, research services leveraging its own platforms for drug screening and disease mechanism studies, and licensing/co-development agreements with strategic partners. Pricing is quote-based with custom enterprise contracts. Go-to-market is event-driven and sales-led: the company exhibits at BIO USA, BIO KOREA, BIO Japan, MPS World Summit, and BIX- BIOPLUS INTERPHEX KOREA, and runs a direct enterprise field-sales motion targeting pharmaceutical and large biotech accounts. Strategic partnerships anchor the technology base, including an exclusive technology transfer agreement with Georgia Tech (commercialized via US subsidiary Mepsgenlab Inc.), co-development with Imperial College London on intestinal/IBD models, and a glioblastoma tumor-microenvironment collaboration with Sungkyunkwan University. The company is recognized as a 2026 Global IP Star Company by the Korean Intellectual Property Office (KIPO) and received the Presidential Citation at the 2025 Venture Entrepreneurship Awards.

Name

Mepsgen

Legal name

MEPSGEN Co., Ltd.

Website

https://mepsgen.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

MEPSGEN is a Korean biotechnology company that develops microphysiological systems (MPS) and microfluidic nanoparticle synthesis platforms — including ProMEPS®, MEPS-X chips, NanoCalibur®, and MST-X — serving pharmaceutical companies, biotech firms, and academic research institutions with drug screening, disease modeling, and scalable nanoparticle drug delivery applications.

Ownership category

akta.pro rank

Product category

Drug Discovery Microphysiological Systems

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)

akta.pro secondary industries

MEMS Actuators & Micro-Mechanisms (Micromirrors/Microfluidics) (HDAHALAJ), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Microphysiological systems
• Organ-on-chip platforms
• Nanoparticle synthesis systems
• Drug discovery tools
• Nanomedicine delivery

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Research Equipment Sales: Sale of proprietary MPS platforms (ProMEPS®, MEPS-X) and nanoparticle synthesis systems (NanoCalibur®, MST-X) to pharmaceutical companies, biotech firms, and research institutions for drug discovery and development.
2. Research Services: Providing research services using company's MPS platforms and technology for drug screening, disease mechanism studies, and early diagnosis applications.
3. Licensing and Co-development: Revenue from strategic partnerships including co-development agreements with pharmaceutical companies for drug delivery technologies and model development, as evidenced by partnerships with Imperial College London and HLB Pharmaceutical.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

MEPSGEN designs, manufactures, and sells microphysiological system (MPS) instruments and microfluidic chips (ProMEPS®, MEPS-X series) alongside automated nanoparticle synthesis systems (NanoCalibur® variants, MST-X microvortex) for pharmaceutical and biotechnology drug discovery, development, and delivery applications. The company also operates a proprietary nanomedicine pipeline (MG-X series) targeting Alzheimer's disease and glioblastoma, and provides contract research services using its platforms.

Product overview

MEPSGEN is a biotechnology company offering an integrated platform of microphysiological systems (MPS) and nanoparticle synthesis technologies for drug development. The core product portfolio includes ProMEPS® (automated MPS modeling system), the MEPS-X series (chip-based tissue barrier and organoid platforms), NanoCalibur® (automated microfluidic nanoparticle synthesis systems from lab to GMP scale), and MST-X (microvortex system for lipid nanoparticle production). The company also operates the MG-X nanomedicine pipeline targeting Alzheimer's disease and brain tumors. These products work together to enable discovery-to-preclinical drug testing workflows using 3D human tissue models combined with scalable nanoparticle manufacturing capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• ProMEPS®: Automated 3D Microphysiological System for High-throughput Screening of Drug Candidates
• MEPS-X
• NanoCalibur®
• MST-X
• MG-X

Products and services

• ProMEPS® Automated 3D Microphysiological System (MPS) that uses robotic operation to deliver highly reproducible, high-throughput modeling and screening of drug candidates across multiple tissue barriers (brain, vasculature, liver, lung, kidney, skin), targeted at pharmaceutical, biotech, and academic drug-discovery laboratories.
• MEPS-X Series Microphysiological System Chips Manufactured plastic microfluidic chip platform enabling organ-level tissue modeling, comprising MEPS-TBC-WL (3D Tissue Barrier Chip, Bottom Well), MEPS-ORD-WL and MEPS-ORD-WU (Organoid-on-a-Chip, Bottom and Upper Well types) and MEPS-TBC-CH (2D Tissue Barrier Chip, Bottom Channel), used by pharma, biotech, and academic researchers for disease modeling and drug screening.
• NanoCalibur® Automated Nanoparticle Synthesis System Automated microfluidic synthesis system for producing nanoparticles with precisely defined properties and tunable scalability, offered in Mini, Lab, Pro, and GMP versions, for use by pharmaceutical, biotech, and nanomedicine developers from research through clinical manufacturing.
• MST-X Microvortex System Microvortex-based microfluidic system for the scalable, high-throughput production of highly uniform lipid nanoparticles encapsulating mRNAs and other payloads, intended for companies developing nanoparticle-based drug delivery and mRNA therapeutics.
• MG-X Nanomedicine Pipeline Proprietary nanoparticle drug-delivery pipeline including MG-PE3 and MG-Sh19 for Alzheimer's disease and MG-GHC24 for glioblastoma brain tumors, positioned as MEPSGEN's therapeutic candidates leveraging its nanoparticle delivery platform.
• Research Services Contract research services performed using MEPSGEN's microphysiological systems and nanoparticle platforms, supporting drug screening, disease-mechanism studies, early diagnosis applications, and nanoparticle formulation work for pharmaceutical, biotech, and academic customers.

Quantifiable outcome

• High-throughput cell and hydrogel injection (32 units)
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• Imperial College LondoncoreStrategic or Co-development Partner · 29 May 2026Partnership to co-develop Inflammatory Bowel Disease (IBD) model using MEPSGEN's MPS platform technology. Also established partnership with Imperial College London's newly established Centre for Intestinal Systems (announced 2026.01.16) for advancing intestinal research models.
• HLB PharmaceuticalcoreStrategic or Co-development Partner · 28 April 2026Strategic partnership to strengthen competitiveness in next-generation drug delivery technologies. Combines HLB Pharmaceutical's drug development capabilities with MEPSGEN's nanoparticle synthesis and drug delivery system expertise.
• Sungkyunkwan UniversitycoreStrategic or Co-development Partner · 4 November 2025Partnership to develop glioblastoma tumor microenvironment model. Leverages university's research capabilities combined with MEPSGEN's tumor-on-a-chip technology (MEPS-TME) for advanced cancer research.
• Georgia Tech (Mepsgenlab Inc.)coreTechnology or IntegrationExclusive technology transfer agreement with Georgia Tech for Microengineered Tissue Barrier System technology. Includes both granted and pending patents. US subsidiary Mepsgenlab Inc. established for commercialization.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Fluigent: Fluigent provides microfluidic flow-control instrumentation and nanoparticle formulation systems, comparable to MEPSGEN's microfluidic instrumentation side and serving similar academic/biopharma research customers.
• Organovo: Organovo develops 3D bioprinted human tissues for drug discovery and disease modeling, an adjacent tissue-engineering approach to MEPSGEN's organ-on-chip MPS platforms for preclinical drug testing.

Direct peers

• InSphero: InSphero provides 3D in vitro microtissue models and Akura flow organ-on-chip platforms, comparable to MEPSGEN's organoid-on-a-chip and 3D tissue barrier offerings for pharma drug screening.
• TissUse: TissUse develops multi-organ-chip (MOC) microphysiological systems for substance testing and disease modeling, competing with MEPSGEN in the MPS hardware and tissue-barrier-chip category.
• CN Bio: CN Bio provides single- and multi-organ MPS platforms (PhysioMimix) used for drug discovery and disease modeling, overlapping with MEPSGEN's ProMEPS® value proposition for preclinical human testing.
• Dolomite Microfluidics: Dolomite (Blacktrace Holdings) supplies microfluidic chips and systems for nanoparticle synthesis and droplet microfluidics, overlapping with MEPSGEN's microfluidic nanoparticle production platforms across lab-scale applications.
• Emulate: Emulate is the leading commercial organ-on-chip company (Liver-Chip, Brain-Chip, etc.), directly competing with MEPSGEN's ProMEPS® and MEPS-X platforms in pharmaceutical preclinical testing and human-relevant disease modeling.
• Mimetas: Mimetas sells the OrganoPlate organ-on-a-chip platform for high-throughput 3D tissue modeling, directly comparable to MEPSGEN's MEPS-X series chips and addressing the same pharma/biotech screening customer base.

Others

• Denali Therapeutics: Denali is a CNS-focused biotech developing therapeutics for neurodegeneration including Alzheimer's, comparable to MEPSGEN's MG-X nanomedicine pipeline (MG-PE3 for Alzheimer's) on the therapeutic-program side rather than the instruments business.

Broad incumbents

• Precision NanoSystems (Cytiva): Precision NanoSystems (now part of Cytiva) is the dominant supplier of microfluidic nanoparticle/LNP manufacturing systems (NanoAssemblr), the most established direct competitor to MEPSGEN's NanoCalibur® and MST-X microvortex systems.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/mepsgen

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds5 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mepsgen